Maria Themeli
Overview
Explore the profile of Maria Themeli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1567
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Schans J, Katsarou A, Kladis G, Bar C, Ramirez M, Themeli M, et al.
J Genet Eng Biotechnol
. 2024 Dec;
22(4):100446.
PMID: 39674638
The past decades have illustrated the power of T-cell engineering in the development of new and successful cell therapies, such as chimeric antigen receptor (CAR) T-cells. Despite clinical success in...
2.
Korst C, ONeill C, Bruins W, Cosovic M, Twickler I, Verkleij C, et al.
J Immunother Cancer
. 2024 Jul;
12(7).
PMID: 39060023
Background: Autologous BCMA-specific CAR T-cell therapies have substantial activity in multiple myeloma (MM). However, due to logistical limitations and BCMA relapses, there is a need for alternatives. UCARTCS1 cells are...
3.
van der Stegen S, Lindenbergh P, Petrovic R, Xie H, Diop M, Alexeeva V, et al.
Nat Biomed Eng
. 2024 Feb;
8(11):1500.
PMID: 38347164
No abstract available.
4.
Netsrithong R, Garcia-Perez L, Themeli M
Front Immunol
. 2024 Jan;
14:1325209.
PMID: 38283344
Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods....
5.
van der Schans J, Wang Z, van Arkel J, van Schaik T, Katsarou A, Ruiter R, et al.
Clin Cancer Res
. 2023 Aug;
29(20):4219-4229.
PMID: 37527004
Purpose: The success of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T cells illustrates the potential of this novel therapy for multiple myeloma. Nonetheless, broadening CAR T-cell therapy beyond...
6.
7.
van der Stegen S, Lindenbergh P, Petrovic R, Xie H, Diop M, Alexeeva V, et al.
Nat Biomed Eng
. 2022 Aug;
6(11):1284-1297.
PMID: 35941192
The production of autologous T cells expressing a chimaeric antigen receptor (CAR) is time-consuming, costly and occasionally unsuccessful. T-cell-derived induced pluripotent stem cells (TiPS) are a promising source for the...
8.
9.
Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, et al.
J Immunother Cancer
. 2022 May;
10(5).
PMID: 35577501
Immunotherapy with gene engineered CAR and TCR transgenic T-cells is a transformative treatment in cancer medicine. There is a rich pipeline with target antigens and sophisticated technologies that will enable...
10.
Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, et al.
J Immunother Cancer
. 2022 May;
10(5).
PMID: 35577500
Despite promising clinical results in a small subset of malignancies, therapies based on engineered chimeric antigen receptor and T-cell receptor T cells are associated with serious adverse events, including cytokine...